From the Department of Anesthesiology, Jikei University School of Medicine, Tokyo, Japan.
Department of Anesthesiology, Mitsui Memorial Hospital, Tokyo, Japan.
Anesth Analg. 2018 May;126(5):1505-1508. doi: 10.1213/ANE.0000000000002562.
We retrospectively investigated the incidence of potential sugammadex-induced anaphylaxis at a single center in Japan over a period of 3 years. The overall incidence of intraoperative hypersensitivity reaction was 0.22% (95% confidence interval [CI], 0.17%-0.29%), and the incidence of anaphylaxis was 0.059% (95% CI, 0.032%-0.10%). The total number of patients who received sugammadex during the study period was 15,479, and the incidence of anaphylaxis associated with sugammadex was 0.039% (n = 6; 95% CI, 0.014%-0.084%). This result implies that the incidence of sugammadex-associated anaphylaxis could be as high as that for succinylcholine or rocuronium. A prospective study, including testing for identification of cause, is necessary to confirm the exact incidence of sugammadex-induced anaphylaxis; however, the present finding calls attention to this potential.
我们回顾性调查了日本某单一中心三年内潜在琥珀酸舒更葡糖钠诱导过敏反应的发生率。术中过敏反应的总体发生率为 0.22%(95%置信区间[CI],0.17%-0.29%),过敏反应的发生率为 0.059%(95%CI,0.032%-0.10%)。研究期间接受琥珀酸舒更葡糖钠治疗的患者总数为 15479 例,与琥珀酸舒更葡糖钠相关的过敏反应发生率为 0.039%(n=6;95%CI,0.014%-0.084%)。这一结果表明,琥珀酸舒更葡糖钠相关过敏反应的发生率可能与琥珀酰胆碱或罗库溴铵相当。需要进行包括病因鉴定测试的前瞻性研究来确认琥珀酸舒更葡糖钠诱导过敏反应的确切发生率;然而,目前的发现引起了对这一潜在风险的关注。